

CITATION REPORT

List of articles citing

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

DOI: 10.1053/jhep.2001.24432
Hepatology, 2001, 33, 1358-64.

Source: <https://exaly.com/paper-pdf/33160530/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
847	Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. 2002 , 97, 2880-5		96
846	Contribution of obesity to hepatitis C-related fibrosis progression. 2002 , 97, 2408-14		172
845	Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. 2002 , 51, 89-94		204
844	Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. 2002 , 30, 65-8		46
843	Hepatobiliary pathology. 2002 , 18, 290-8		
842	Nonalcoholic fatty liver disease. 2002 , 346, 1221-31		3875
841	Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. 2002 , 34, 204-11		87
840	Is insulin resistance a pathogenic co-factor in hepatitis C virus-related disease and hepatocellular carcinoma?. 2002 , 34, 151		
839	Obesity and liver disease. 2002 , 16, 703-16		87
838	Nonalcoholic fatty liver disease. 2002 , 122, 1649-57		689
837	AGA technical review on nonalcoholic fatty liver disease. 2002 , 123, 1705-25		802
836	Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. 2002 , 99, 4588-91		121
835	Leptin is essential for the hepatic fibrogenic response to chronic liver injury. 2002 , 37, 206-13		321
834	Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. 2002 , 37, 837-42		227
833	Does hepatitis C virus cause severe liver disease only in people who drink alcohol?. 2002 , 2, 303-9		22
832	[Role of interferons in the treatment of hepatitis B and hepatitis C virus infections]. 2002 , 23 Suppl 4, 459s-474s		2
831	Hepatitis B and hepatitis C. 2002 , 6, 317-34, v		29

830	The liver in obesity and type 2 diabetes mellitus. 2002 , 6, 867-77		33
829	Fibrosis and disease progression in hepatitis C. <i>Hepatology</i> , 2002 , 36, S47-S56	11.2	217
828	Hepatocellular carcinoma and hepatitis C in the United States. <i>Hepatology</i> , 2002 , 36, S74-S83	11.2	263
827	The role of liver biopsy in chronic hepatitis C. <i>Hepatology</i> , 2002 , 36, S152-S160	11.2	155
826	Steatosis, steatohepatitis: Review of effects on chronic hepatitis C. 2002 , 1, 38-44		9
825	Non-alcoholic steatohepatitis: definitions and pathogenesis. 2002 , 17 Suppl 3, S377-84		124
824	Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. 2002 , 17, 873-81		135
823	Interaction of non-alcoholic fatty liver disease with other liver diseases. 2002 , 16, 767-81		41
822	Pathogenesis of steatohepatitis. 2002 , 16, 663-78		305
821	Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. <i>Hepatology</i> , 2002 , 36, 729-36	11.2	258
820	Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. <i>Hepatology</i> , 2002 , 36, 1266-72	11.2	272
819	The role of liver biopsy in chronic hepatitis C. <i>Hepatology</i> , 2002 , 36, S152-60	11.2	115
818	Hepatocellular carcinoma and hepatitis C in the United States. <i>Hepatology</i> , 2002 , 36, S74-83	11.2	188
817	Fibrosis and disease progression in hepatitis C. <i>Hepatology</i> , 2002 , 36, S47-56	11.2	173
816	Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always. <i>Hepatology</i> , 2002 , 36, 1050-2	11.2	35
815	Hepatitis C: magnitude of the problem. 2002 , 8, S3-6		29
814	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003 , 38, 75-85	11.2	448
813	High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. <i>Hepatology</i> , 2003 , 38, 639-44	11.2	276

812	Obesity and its nurturing effect on hepatitis C. <i>Hepatology</i> , 2003 , 38, 557-9	11.2	26
811	Steatosis in hepatitis C: What does it mean?. 2003 , 2, 137-144		2
810	Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. 2003 , 97, 3036-43		256
809	Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma?. 2003 , 97, 2948-50		4
808	Impact of oestrogens on the progression of liver disease. 2003 , 23, 63-9		145
807	Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. 2003 , 18, 386-92		62
806	Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. 2003 , 33, 500-4		12
805	Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. 2003 , 17, 1031-7		86
804	Trying to catch the HCV virus in its 'battle field'. 2003 , 10 Suppl 1, S77-8		0
803	Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. 2003 , 16, 49-56		131
802	Antiretroviral-associated liver injury. 2003 , 7, 475-99		41
801	Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. 2003 , 125, 1053-9		87
800	Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. 2003 , 125, 1695-704		594
799	Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. 2003 , 98, 2751-6		113
798	Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. 2003 , 38, 223-9		94
797	Rate of natural disease progression in patients with chronic hepatitis C. 2003 , 38, 307-14		69
796	In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. 2003 , 39, 1042-8		145
795	Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. 2003 , 125, 1796-807		402

794	Hyperlactataemia syndromes associated with HIV therapy. 2003 , 3, 329-37	99
793	Hepatitis C virus genetic variability: pathogenic and clinical implications. 2003 , 7, 45-66	165
792	Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. 2003 , 52, 288-92	227
791	Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. 2003 , 52, 1638-43	92
790	Hepatitis C virus. 2003 , 127-171	
789	Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. 2003 , 98, 2064-71	144
788	Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. 2003 , 96, 699-709	41
787	A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. 2003 , 98, 952-5	13
786	Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. 2003 , 98, 1135-41	77
785	Managing antiretroviral-associated liver disease. 2003 , 34 Suppl 1, S34-9	15
784	Hepatitis C and alcohol: interactions, outcomes, and implications. 2003 , 36, 242-52	119
783	Steatosis and fibrosis in patients with chronic hepatitis C. 2004 , 57, 402-6	29
782	Fatty liver, hypertension, and the metabolic syndrome. 2004 , 53, 923-4	39
781	Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. 2004 , 53, 420-4	102
780	Steatosis affects chronic hepatitis C progression in a genotype specific way. 2004 , 53, 406-12	204
779	Predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C. 2004 , 38, 1789-90; author reply 1790	3
778	Fibrosis progression in chronic hepatitis C virus infection. 2004 , 53, 318-21	68
777	HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. 2004 , 38 Suppl 2, S65-72	87

776	Management of chronic hepatitis C virus infection: a new era of disease control. 2004 , 34, 324-37		20
775	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. 2004 , 5, 27-42		224
774	The management of side-effects during therapy for hepatitis C. 2004 , 20, 917-29		42
773	Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. 2004 , 11, 455-8		78
772	Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. 2004 , 11, 479-87		55
771	[Obesity and alcoholic and viral chronic liver disease]. 2004 , 28, 268-71		1
770	Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. 2004 , 28, 272-8		39
769	Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?. 2004 , 49, 25-9		47
768	Non-alcoholic fatty liver disease: an emerging pathological spectrum. 2004 , 444, 3-12		81
767	Factors influencing the rate of fibrosis progression in chronic hepatitis C. 2004 , 49, 1971-6		27
766	Nicht alkoholische Fettleberkrankheit (NAFLK). 2004 , 152, 864-869		
765	Fat, diabetes, and liver injury in chronic hepatitis C. 2004 , 6, 22-9		34
764	When to treat patients with chronic hepatitis C. 2004 , 6, 261-3		
763	Chronic hepatitis C and steatosis. 2004 , 3, 123-128		18
762	The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. 2004 , 11, 91-6		63
761	Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. <i>Hepatology</i> , 2004 , 40, 933-941	11.2	2
760	Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. <i>Hepatology</i> , 2004 , 39, 333-42	11.2	169
759	Host factors and failure of interferon-alpha treatment in hepatitis C virus. <i>Hepatology</i> , 2004 , 39, 880-90	11.2	130

758	Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. <i>Hepatology</i> , 2004 , 39, 1230-8	11.2	120
757	Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. <i>Hepatology</i> , 2004 , 39, 1239-47	11.2	145
756	Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. <i>Hepatology</i> , 2004 , 40, 933-41	11.2	163
755	Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. 2004 , 10, 599-606		21
754	Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. 2004 , 10, 699-702		23
753	Genetic diversity and evolution of hepatitis C virus--15 years on. 2004 , 85, 3173-3188		701
752	The histologic spectrum of nonalcoholic fatty liver disease. 2004 , 8, 481-500, vii		47
751	Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. 2004 , 126, 586-97		368
750	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. 2004 , 53, 413-9		310
749	Hepatitis C and steatosis. 2004 , 8, 881-92, ix		12
748	Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class 1. 2004 , 65, 745-51		34
747	The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. 2004 , 40, 484-90		312
746	Hepatitis C virus genotype 1 associated with massive steatosis of the liver and hypo-beta-lipoproteinemia. 2004 , 40, 562-3		9
745	Hepatitis C virus and liver steatosis: when fat is not beautiful. 2004 , 40, 533-5		19
744	NASH: are genes blowing the hits?. 2004 , 40, 853-6		11
743	A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 2004 , 41, 312-8		6
742	Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment. 2004 , 41, 156-66		20
741	Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. 2004 , 41, 644-51		20

740	HIV and hepatitis C virus co-infection. 2004 , 4, 437-44	135
739	Global burden of disease (GBD) for hepatitis C. 2004 , 44, 20-9	375
738	Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. 2004 , 40, 147-54	94
737	Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C. 2004 , 16, 761-5	6
736	The epidemiology of fatty liver. 2004 , 16, 1087-93	94
735	Special considerations in the initiation and management of antiretroviral therapy in individuals coinfecting with HIV and hepatitis C. 2004 , 18, 2221-34	28
734	Long-term outcome of hepatitis C infection after bone marrow transplantation. 2004 , 103, 1618-24	143
733	The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. 2004 , 103, 2460-6	82
732	Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. 2005 , 17, 149-53	33
731	Hepatic steatosis and antiretroviral drug use among adults coinfecting with HIV and hepatitis C virus. 2005 , 19, 585-92	138
730	Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. 2005 , 20, 1395-400	37
729	Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavirin. 2005 , 21, 1173-8	11
728	Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications. 2005 , 22 Suppl 2, 48-51	31
727	Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications. 2005 , 22 Suppl 2, 52-5	47
726	HCV liver infection and liver steatosis: evidence for indirect mechanisms in genotype 3?. 2005 , 22 Suppl 2, 79-82	225
725	Concluding remarks: metabolic syndrome, liver and HCV. 2005 , 22 Suppl 2, 83-5	7
724	Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. 2005 , 22, 943-9	10
723	Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. <i>Hepatology</i> , 2005 , 41, 82-7	11.2 142

722	Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. <i>Hepatology</i> , 2005 , 41, 809-18	11.2	284
721	Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , 2005 , 41, 995-1003	11.2	87
720	Mild chronic hepatitis C with steatosis: which treatment?. <i>Hepatology</i> , 2005 , 41, 1198	11.2	1
719	Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2005 , 42, 63-71	11.2	220
718	The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. <i>Hepatology</i> , 2005 , 42, 113-20	11.2	62
717	Steatosis: co-factor in other liver diseases. <i>Hepatology</i> , 2005 , 42, 5-13	11.2	290
716	Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C mono-infection. <i>Hepatology</i> , 2005 , 42, 310-6	11.2	53
715	Hepatocyte expression of minichromosome maintenance protein-2 predicts fibrosis progression after transplantation for chronic hepatitis C virus: a pilot study. 2005 , 11, 427-33		16
714	In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. 2005 , 40, 617-24		33
713	Pathogenesis of recurrent hepatitis C after liver transplantation. 2005 , 4, 138-144		1
712	Obesity, insulin resistance, and HCV: Implications for pathogenesis. 2005 , 4, 153-157		2
711	Nonalcoholic fatty liver disease: a clinical review. 2005 , 50, 171-80		200
710	The endocannabinoid system in chronic liver disease. 2005 , 4, 248-254		15
709	Insulin resistance and steatosis in hepatitis C virus infection. 2005 , 54, 903-6		44
708	Recent Therapeutic Developments in Hepatic Fibrosis. 2005 , 122-142		
707	Nonalcoholic Fatty Liver (NAFL): Overview. 2005 , 1-43		
706	Negative cross-talk between Nur77 and small heterodimer partner and its role in apoptotic cell death of hepatoma cells. 2005 , 19, 950-63		45
705	Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. 2005 , 100, 2010-8		28

704	Hepatitis C virus-induced hepatocellular steatosis. 2005 , 100, 711-5		63
703	Proteome analysis of liver cells expressing a full-length hepatitis C virus (HCV) replicon and biopsy specimens of posttransplantation liver from HCV-infected patients. 2005 , 79, 7558-69		74
702	Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. 2005 , 40, e101-9		43
701	Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. 2005 , 54, 1003-8		285
700	Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. 2005 , 54, 1590-6		75
699	Management of chronic hepatitis C. 2005 , 81, 376-82		21
698	Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. 2005 , 86, 2185-2196		63
697	TNF- α , chronic hepatitis C and diabetes: a novel triad. 2005 , 98, 1-6		117
696	Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. 2005 , 19, 621-3		6
695	Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 390-6	6.9	70
694	Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. 2005 , 9, 617-34, vi		26
693	Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 67-74	6.9	246
692	Natural history of hepatitis C. 2005 , 9, 383-98, vi		281
691	Hepatic complications of obesity. 2005 , 34, 45-61		23
690	Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. 2005 , 280, 37481-8		310
689	Is liver disease a threat to patients with metabolic disorders?. 2005 , 37, 333-46		22
688	An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. 2005 , 42, 744-51		145
687	Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. 2005 , 43, 38-44		140

686	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. 2005 , 43, 235-42	59
685	Adiponectin and its receptors in patients with chronic hepatitis C. 2005 , 43, 929-36	86
684	TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. 2005 , 43, 944-50	32
683	Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. 2005 , 90, 2240-3	85
682	Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. 2005 , 128, 33-42	173
681	Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. 2005 , 128, 627-35	63
680	Steatosis is a cofactor in liver injury in hemochromatosis. 2005 , 129, 1937-43	129
679	Steatosis and chronic hepatitis C virus infection: mechanisms and significance. 2005 , 9, 399-410, vi	22
678	Hepatic steatosis and HIV infection. 2005 , 19, 356-65	37
677	Acute and chronic hepatitis. 2006 , 23, 132-48	18
676	The evolving role of leptin and adiponectin in chronic liver diseases. 2006 , 101, 2629-40	145
675	Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. 2006 , 10, 793-819	14
674	American Gastroenterological Association technical review on the management of hepatitis C. 2006 , 130, 231-64; quiz 214-7	312
673	Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. 2006 , 130, 1636-42	449
672	Chronic hepatitis C virus infection: genotyping and its clinical role. 2006 , 1, 103-12	37
671	Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis. 2006 , 29, 1140-1149	90
670	The changing epidemiology and natural history of hepatitis C virus infection. 2006 , 10, 697-715	71
669	Hepatic steatosis and insulin resistance: does etiology make a difference?. 2006 , 44, 190-6	116

668	Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. 2006 , 44, S28-34	56
667	Natural history and predictors of disease severity in chronic hepatitis C. 2006 , 44, S19-24	371
666	HCV therapy in 2006: down with ALT levels, in with awareness of co-existent metabolic syndrome. 2006 , 44, 624-6	2
665	Is HCV infection associated with liver steatosis also in children?. 2006 , 45, 350-4	16
664	Insulin resistance and HCV: will new knowledge modify clinical management?. 2006 , 45, 514-9	44
663	Is HCV infection associated with liver steatosis also in children?. 2006 , 45, 758-759	1
662	The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. 2006 , 38, 1440-4	8
661	[Steatosis and non-alcoholic steatohepatitis in patients with chronic hepatitis due to hepatitis C virus infection]. 2006 , 43, 265-8	2
660	Insulin resistance and hepatitis C. <i>World Journal of Gastroenterology</i> , 2006 , 12, 7075-80	5.6 120
659	Steatosis and hepatitis C in an Alaska Native/American Indian population. 2006 , 65, 253-60	4
658	Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. 2006 , 18, 233-7	124
657	Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. 2006 , 87, 1-16	527
656	Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. 2006 , 26, 166-72	35
655	Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. 2006 , 26, 1119-25	42
654	Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. 2006 , 13, 199-205	40
653	Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. 2006 , 13, 303-10	80
652	Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. 2006 , 13, 449-56	17
651	Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. 2006 , 23, 107-14	100

650	Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. 2006 , 24, 507-12		26
649	Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. 2006 , 24, 1349-57		91
648	Histological assessment of non-alcoholic fatty liver disease. 2006 , 49, 450-65		210
647	Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. 2006 , 13, 23-30		72
646	Hepatitis C and steatosis: a reappraisal. 2006 , 13, 73-80		117
645	Leptin in the field of hepatic fibrosis: a pivotal or an incidental player?. 2006 , 51, 1685-96		19
644	Nonalcoholic fatty liver disease and HIV infection. 2006 , 3, 113-7		7
643	[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. 2006 , 30, 1281-95		3
642	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 64-71	11.2	147
641	Hepatitis C -- identifying patients with progressive liver injury. <i>Hepatology</i> , 2006 , 43, S194-206	11.2	71
640	Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. <i>Hepatology</i> , 2006 , 43, 780-7	11.2	61
639	Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 1337-45	11.2	74
638	Impact of obesity on treatment of chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 1177-86	11.2	106
637	Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. <i>Hepatology</i> , 2006 , 44, 472-7	11.2	171
636	HepatoProteomics: applying proteomic technologies to the study of liver function and disease. <i>Hepatology</i> , 2006 , 44, 299-308	11.2	46
635	Global challenges in liver disease. <i>Hepatology</i> , 2006 , 44, 521-6	11.2	587
634	Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. <i>Hepatology</i> , 2006 , 44, 1122-38	11.2	75
633	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <i>Hepatology</i> , 2006 , 44, 1648-55	11.2	126

632	Nonalcoholic fatty liver disease and liver transplantation. 2006 , 12, 523-34	108
631	Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. 2006 , 78, 452-8	72
630	Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. 2006 , 41, 180-5	29
629	Hepatic steatosis in HIV-HCV coinfecting patients: analysis of risk factors. 2006 , 20, 525-31	64
628	Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. 2006 , 43, 365-72	130
627	Steatosis in chronic hepatitis C: why does it really matter?. 2006 , 55, 123-30	281
626	Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. 2006 , 101, 983-92	52
625	Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. 2006 , 42, 1032-9	45
624	Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. 2007 , 56, 390-5	89
623	Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. 2007 , 102, 634-41	32
622	Impact of steatosis on insulin secretion in chronic hepatitis C patients. 2007 , 102, 2173-80	7
621	Innate immune system regulation of nuclear hormone receptors in metabolic diseases. 2007 , 82, 187-95	17
620	Hypertension and fatty liver: guilty by association?. 2007 , 21, 264-70	32
619	Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. 2007 , 21, 583-8	21
618	Hepatitis C and insulin resistance: mutual interactions. A review. 2007 , 62, 111-9	12
617	Fatty liver in chronic hepatitis C infection: unravelling the mechanisms. 2007 , 56, 1186-8	7
616	Non-alcoholic fatty liver disease in patients with HCV genotype 4. 2007 , 56, 1170-1	3
615	The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. 2007 , 56, 1302-8	78

614	Hepatitis C in children: recent advances. 2007 , 19, 570-4	10
613	A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C. 2007 , 41, 416-21	15
612	Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses. 2007 , 19, 671-7	15
611	Prevalence of and factors associated with hepatic steatosis in patients coinfecting with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. 2007 , 45, 168-73	26
610	Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. 2007 , 46, 999-1008	136
609	Hepatitis C virus: the viral way to fatty liver. 2007 , 46, 985-7	18
608	Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. 2007 , 47, 556-64	154
607	Outcome of hepatitis C infection: bleak or benign?. 2007 , 47, 4-6	8
606	Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: is it really different, and if so, why?. 2007 , 47, 447-50	9
605	Protection of estrogens against the progression of chronic liver disease. 2007 , 37, 239-47	79
604	High molecular weight form of adiponectin levels of Japanese patients with chronic hepatitis C virus infection. 2007 , 37, 1052-61	7
603	Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-beta liver expression. 2008 , 38, 141-6	8
602	Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. 2007 , 11, 173-89, x	34
601	Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. 2007 , 21, 479-91	45
600	Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. 2007 , 242, 450-5	134
599	Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 245-54	6.9 40
598	Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. 2007 , 132, 2557-76	4148
597	Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. 2007 , 39, 936-42	37

596	What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?. 2007 , 6, 92-96		14
595	Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. <i>Hepatology</i> , 2007 , 45, 569-78	11.2	88
594	Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. <i>Hepatology</i> , 2007 , 46, 66-73	11.2	112
593	Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. <i>Hepatology</i> , 2007 , 46, 380-7	11.2	109
592	Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. 2007 , 109, 2490-6		153
591	Translation efficiencies of the 5'-untranslated region of genotypes 1a and 3a in hepatitis C infected patients. 2007 , 79, 259-69		4
590	Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C. 2007 , 22, 1621-6		10
589	Obesity management in liver clinics: translation of research into clinical practice. 2007 , 22, 504-9		20
588	Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. 2007 , 14, 11-21		14
587	Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. 2007 , 14, 29-35		63
586	Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. 2007 , 14, 600-7		45
585	Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. 2007 , 14, 714-20		7
584	Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. 2008 , 15, 129-36		31
583	Hepatitis C virus core protein, lipid droplets and steatosis. 2008 , 15, 157-64		53
582	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 2007 , 25, 1181-91		59
581	Hepatic steatosis in HIV-HCV coinfecting patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. 2007 , 26, 1489-98		35
580	Obesity did not diminish the efficacy of percutaneous ablation for hepatocellular carcinoma. 2007 , 27, 360-7		7
579	HIV/HCV co-infection: histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: a review article. 2007 , 27, 598-606		16

578	Impact of non-alcoholic fatty liver disease on chronic hepatitis B. 2007 , 27, 607-11	78
577	Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. 2008 , 28, 370-6	26
576	Hepatitis C and steatosis. 2007 , 38, 621-7	42
575	Risks factors of liver fibrosis in a cohort of intravenous drug users coinfectd with HIV and HCV in the HAART era: the role of mixed steatosis. 2007 , 31, 822-7	4
574	[Natural history of factors influencing the severity of chronic HCV infection in HIV-HCV coinfectd patients]. 2007 , 31, 881-6	2
573	[Steatosis, chronic hepatitis virus C infection and homocysteine]. 2007 , 31, 415-20	16
572	[Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]. 2007 , 31, 643-54	3
571	Alcool, syndrome mtabolique et obfit: impact sur la rponse au traitement. 2007 , 31, 40-43	2
570	Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. 2007 , 24, 972-82	8
569	Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. 2007 , 52, 570-8	24
568	Apolipoprotein-All concentrations are associated with liver steatosis in patients with chronic hepatitis C. 2007 , 52, 3431-4	5
567	The impact of steatosis and alcohol on hepatitis C. 2007 , 6, 39-45	
566	Mechanisms of glucose intolerance in patients with chronic hepatitis C: implications for treatment. 2007 , 9, 110-5	0
565	Comment, en Afrique, gfer les comorbiditš en hpatologie?. 2007 , 1, 63-70	
564	Are HCV genotypes 2 and 3 the same or different?. 2008 , 7, 88-92	1
563	Chronic hepatitis C in the Latino population. 2008 , 7, 106-112	2
562	Dysmetabolic changes associated with HCV: a distinct syndrome?. 2008 , 3, 99-108	22
561	Adipocytokines and liver disease. 2008 , 43, 811-22	136

560	Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. 2008 , 14, 193-201		50
559	Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. <i>Hepatology</i> , 2008 , 48, 16-27	11.2	62
558	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008 , 48, 28-37	11.2	49
557	Insulin resistance in chronic hepatitis C, genotypes 1 and 4: the unfortunate reality. <i>Hepatology</i> , 2008 , 47, 2137-9	11.2	5
556	Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2008 , 48, 723-31	11.2	98
555	Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease. 2008 , 14, 586-597		3
554	Obesity and overweight in relation to liver disease mortality in men: 38 year follow-up of the original Whitehall study. 2008 , 32, 1741-4		10
553	Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. 2008 , 28, 339-46		8
552	Steatosis in chronic hepatitis C: friend or foe?. 2008 , 28, 294-6		2
551	Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. 2008 , 23, 1082-8		76
550	Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime. 2008 , 27, 855-65		24
549	Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. 2008 , 15, 740-6		38
548	Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?. 2008 , 1, 46		9
547	Bone marrow cells play only a very minor role in chronic liver regeneration induced by a choline-deficient, ethionine-supplemented diet. 2008 , 1, 195-204		5
546	Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. 2008 , 12, 805-24, ix		26
545	Steatosis and metabolic syndrome: An emerging enigma in the natural history of chronic hepatitis C. 2008 , 7, 60-63		
544	Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. 2008 , 134, 416-23		399
543	Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. 2008 , 134, 432-9		150

542	Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. 2008 , 134, 1699-714	163
541	Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. 2008 , 135, 111-21	408
540	Hepatitis C infection and nonalcoholic fatty liver disease. 2008 , 12, 573-85, viii-ix	25
539	Latinos and chronic hepatitis C: a singular population. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 484-90	6.9 30
538	[Managing comorbidities in hepatology: toward a more holistic medicine]. 2008 , 37, 1274-80	
537	Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. 2008 , 48, 399-406	87
536	The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. 2008 , 48, 736-42	30
535	Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. 2008 , 48, 756-64	36
534	Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. 2008 , 49, 429-40	82
533	Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. 2008 , 49, 1046-54	41
532	Treatment predictors of a sustained virologic response in hepatitis B and C. 2008 , 49, 634-51	263
531	L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. 2008 , 53, 1114-21	29
530	Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. 2008 , 38, 291-9	43
529	Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. 2008 , 38, 348-53	43
528	Hepatitis C virus and glucose and lipid metabolism. 2008 , 34, 692-700	18
527	Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 584-9	6.9 43
526	Hepatitis C virus infection and hepatocellular carcinoma. 2008 , 12, 661-74, x	34
525	Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. 2008 , 12, 209-18	12

- 524 Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. **2008**, 82, 2606-12 139
- 523 Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. **2008**, 48, 169-76 7
- 522 Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. **2008**, 2, 207-15 20
- 521 Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. **2008**, 103, 605-14 45
- 520 Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. **2008**, 103, 1136-44 149
- 519 Liver transplantation in HIV-positive patients. **2008**, 2, 39-46 3
- 518 The role of hepatitis C virus in the pathogenesis of hepatocellular carcinoma. **2008**, 1, 167-175 10
- 517 Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. **2008**, 197, 283-91 59
- 516 Evaluation of the severity of chronic hepatitis C with 3-T1H-MR spectroscopy. **2008**, 190, 1331-9 23
- 515 Nonalcoholic fatty liver disease: from clinical recognition to treatment. **2008**, 2, 59-79 10
- 514 Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil. **2008**, 22, 701-7 9
- 513 Liver disease in injection drug users with hepatitis C, with and without HIV coinfection. **2008**, 27, 49-59 74
- 512 Acute and Chronic Infectious Hepatitis. **2009**, 1003-1033
- 511 Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. **2009**, 23, 273-8 24
- 510 Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress. **2009**, 1, 126-43 36
- 509 Insulin resistance and steatosis in chronic hepatitis C. **2009**, 8, S67-S75 31
- 508 Hyperferritinemia is a risk factor for steatosis in chronic liver disease. *World Journal of Gastroenterology*, **2009**, 15, 2132-8 5.6 27
- 507 Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites. **2009**, 104, 1686-92 28

506	Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection. 2009 , 52, 49-56		8
505	Domain 3 of hepatitis C virus core protein is sufficient for intracellular lipid accumulation. 2009 , 200, 1781-8		15
504	Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. 2009 , 50, 2193-202		35
503	Hepatocarcinogenesis following pancreatic islet transplantation in streptozotocin- and autoimmune-diabetic rats. 2009 , 115, 97-104		1
502	Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. 2009 , 44, 6-14		48
501	Direct imaging of the disruption of hepatitis C virus replication complexes by inhibitors of lipid metabolism. 2009 , 394, 130-42		53
500	Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. 2009 , 583, 2720-6		41
499	Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. <i>Hepatology</i> , 2009 , 49, 436-42	11.2	102
498	Liver biopsy. <i>Hepatology</i> , 2009 , 49, 1017-44	11.2	1386
497	Adipokines in liver diseases. <i>Hepatology</i> , 2009 , 50, 957-69	11.2	350
496	What's in a NAME?. <i>Hepatology</i> , 2009 , 50, 663-7	11.2	22
495	Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. 2009 , 15, 37-48		64
494	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. 2009 , 15, 619-28		34
493	When to treat and the benefits of treating hepatitis C in patients with haemophilia. 2009 , 15, 20-32		7
492	The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. 2009 , 16, 492-9		37
491	Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. 2009 , 16, 681-8		44
490	Chemerin, vaspin and insulin resistance in chronic hepatitis C. 2010 , 17, 661-7		41
489	Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). 2009 , 67, 280-7		12

488	Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. 2009 , 24, 1669-76	72
487	Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. 2009 , 29, 153-8	8
486	Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. 2009 , 29, 213-20	28
485	Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks. 2009 , 29, 237-41	13
484	Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C. 2009 , 29, 557-65	21
483	The history of the "natural history" of hepatitis C (1968-2009). 2009 , 29 Suppl 1, 89-99	173
482	The global burden of hepatitis C. 2009 , 29 Suppl 1, 74-81	1012
481	Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. 2009 , 29 Suppl 2, 3-12	40
480	Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. 2009 , 29, 878-83	33
479	Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. 2009 , 51, 655-66	217
478	Endocrine manifestations of hepatitis C virus infection. 2009 , 5, 26-34	87
477	Metabolic disorders and chronic viral disease: the case of HIV and HCV. 2009 , 35, 1-11	21
476	Lipid droplets and hepatitis C virus infection. 2009 , 1791, 552-9	71
475	[Factors associated with hepatic steatosis in human immunodeficiency virus and hepatitis C virus coinfecting patients]. 2009 , 132, 208-13	6
474	[Hepatic steatosis in chronic hepatitis C: study of risk factors and relationship with the fibrosis stage]. 2009 , 132, 574-9	2
473	Hepatic steatosis is uncommon in children with chronic hepatitis B. 2009 , 46, 360-2	5
472	Forewarned is forearmed. 2009 , 51, 626-7	2
471	The role of the endocannabinoid system in liver diseases. 2009 , 23, 65-77	29

470	Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. 2009 , 41, 586-90	5
469	Liver HCV-antigens and steatosis in chronic hepatitis C: role of different genotypes. 2009 , 41, 659-64	
468	Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. 2009 , 104, 598-604	32
467	Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. 2009 , 44, 752-9	40
466	Psychosocial issues and mental health treatment recommendations for patients with hepatitis C. 2009 , 50, 114-22	16
465	Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: analysis using mouse model and cultured cells. 2009 , 175, 1515-24	9
464	Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. 2009 , 39, 724-38	72
463	Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. 2009 , 39, 795-804	5
462	Hepatitis C and diabetes: the inevitable coincidence?. 2009 , 7, 293-308	54
461	Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. 2009 , 104, 605-16	31
460	Molecular mechanisms of insulin resistance in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2009 , 15, 4356-64	5.6 55
459	Visceral obesity and hypoadiponectinemia are significant determinants of hepatic dysfunction: An epidemiologic study of 3827 Japanese subjects. 2009 , 43, 995-1000	21
458	Long-term outcomes after treatment with interferon and ribavirin in HCV patients. 2009 , 43, 661-71	24
457	Prevalence and predictors of hepatic steatosis in adults with newly diagnosed chronic liver disease due to hepatitis C. 2009 , 88, 302-306	4
456	Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. 2010 , 55, 228-31	12
455	Diab�e et infection par le virus de l'h�patite C. 2010 , 7, 1-7	0
454	Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era. 2010 , 90, 530-9	69
453	Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. 2010 , 44, 707-12	14

452	Low-fat diet: case study of a cardiology patient. 2010 , 40, 235-242		0
451	Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication. 2010 , 285, 25602-12		51
450	Cellular lipid droplets and hepatitis C virus life cycle. 2010 , 33, 355-9		25
449	Ultrastructural and quantitative analysis of the lipid droplet clustering induced by hepatitis C virus core protein. 2010 , 67, 3151-61		24
448	Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. 2010 , 45, 95-104		24
447	Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. 2010 , 45, 1053-62		35
446	Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary. 2010 , 16, 149-57		0
445	Ethnic and Racial Differences in the Natural History of Hepatitis C. 2010 , 9, 106-112		
444	Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. 2010 , 55, 2049-57		18
443	Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). 2010 , 7, 13		32
442	Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. <i>Hepatology</i> , 2010 , 52, 1143-55	11.2	120
441	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010 , 52, 1543-52	11.2	76
440	Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?. 2010 , 82, 958-64		7
439	Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. 2010 , 12, 625-36		52
438	Comorbidities associated with the increasing burden of hepatitis C infection. 2010 , 30, 1012-8		45
437	Viral hepatocarcinogenesis. 2010 , 29, 2309-24		207
436	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. 2010 , 25, 970-7		27
435	Hepatitis B and C. 2010 , 186-199		

434	An assessment of the use of chimpanzees in hepatitis C research past, present and future: 2. Alternative replacement methods. 2010 , 38, 471-94		6
433	Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. 2010 , 2, 87-96		5
432	Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C. 2010 , 24, 445-51		13
431	Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy. 2010 , 1, 115-28		11
430	Hepatitis C and hepatic steatosis. 2010 , 103, 293-303		11
429	Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. 2010 , 24, 811-7		7
428	Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 924-33; quiz e117	6.9	93
427	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. 2010 , 42, 272-82		159
426	Nonalcoholic Fatty Liver Disease. 2010 , 1153-1179		
425	Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study. 2010 , 52, 16-24		36
424	Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. 2010 , 53, 1000-5		26
423	Oxidative stress and nutritional factors in hepatitis C virus-positive liver recipients, controls, and hepatitis C virus-positive nontransplant patients. 2010 , 42, 1744-9		4
422	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. 2010 , 40, 251-60		53
421	The importance of steatosis in chronic hepatitis C infection and its management: A review. 2010 , 40, 237-47		17
420	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. 2010 , 40, 870-7		56
419	Restriction of calorie and iron intake results in reduction of visceral fat and serum alanine aminotransferase and ferritin levels in patients with chronic liver disease. 2010 , 40, 1188-94		19
418	Hepatitis C infection and metabolic syndrome. 2010 , 109, 403-7		8
417	Ethnicity and body mass index are associated with hepatitis C presentation and progression. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 72-8	6.9	30

416	Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: a comparative analysis of nine scoring methods. 2010 , 45, 51-9	3
415	Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. 2010 , 84, 5936-46	54
414	Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. 2011 , 140, 469-77	58
413	Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate!. 2011 , 140, 772-5	8
412	Systems Biology and Animal Nutrition: Insights from the Dairy Cow during Growth and the Lactation Cycle. 2011 , 215-245	6
411	Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases. 2011 , 12, 136-8	5
410	Metabolic alterations and chronic hepatitis C: treatment strategies. 2011 , 12, 2215-34	55
409	[Role of homocysteine in liver steatosis associated with virus C hepatitis]. 2011 , 136, 61-2	
408	Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. 2011 , 54, 432-8	38
407	Viral genotype-specific role of PNPLA3, PPARG, MTP, and IL28B in hepatitis C virus-associated steatosis. 2011 , 55, 529-535	89
406	No increase in the expression of key unfolded protein response genes in HCV genotype 3 patients with severe steatosis. 2011 , 160, 420-3	2
405	Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort. 2011 , 41, 530-41	15
404	Chronic viral hepatitis: the histology report. 2011 , 43 Suppl 4, S331-43	34
403	Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis. 2011 , 48, 179-85	
402	Contribuição da ultrassonografia para o diagnóstico das alterações histopatológicas presentes na hepatite C crônica, com ênfase na esteatose hepática: Parte I. 2011 , 44, 141-146	5
401	Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C. 2011 , 45, 76-82	14
400	Prophylactic analgesia before percutaneous liver biopsy: a clinical comparative study. 2011 , 23, 782-6	7
399	[Fatty liver and hepatitis C virus infection]. 2011 , 152, 1513-9	1

398	Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome. 2011 , 50, 1137-41	8
397	Extended criteria donors in liver transplant candidates with hepatorenal syndrome. 2011 , 25, E257-63	2
396	Hepatic steatosis and hepatitis C: Still unhappy bedfellows?. 2011 , 26 Suppl 1, 96-101	34
395	Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. 2011 , 26, 1182-8	17
394	Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. 2011 , 18, 53-60	13
393	HCV synergizes with body weight in the promotion of insulin resistance. 2011 , 18, 135-41	4
392	The hepatitis C self-management programme: a randomized controlled trial. 2011 , 18, 358-68	14
391	Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort. 2011 , 18, e144-52	19
390	HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. 2011 , 18, e516-22	132
389	Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. 2011 , 18, 745-59	117
388	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 2011 , 31, 507-15	58
387	The interaction between HCV and nuclear receptor-mediated pathways. 2011 , 132, 30-8	5
386	HCV genotype-specific correlation with serum markers: higher predictability for genotype 4a. 2011 , 8, 293	8
385	A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. 2011 , 8, 53	26
384	The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. 2011 , 21, 87-97	338
383	Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. 2011 , 56, 2145-51	30
382	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. 2011 , 46, 401-9	31
381	Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. 2011 , 46, 529-35	12

380	Hepatitis C virus and lipid profiles: more questions than answers?. 2011 , 5, 865-7		2
379	A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). 2011 , 11, 44		55
378	The role of lifestyle changes in the management of chronic liver disease. 2011 , 9, 70		36
377	Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. 2011 , 17, 1380-6		31
376	Evidence for extensive genotypic diversity and recombination of GB virus C (GBV-C) in Germany. 2011 , 83, 685-94		19
375	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. <i>Hepatology</i> , 2011 , 53, 791-9	11.2	199
374	Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production. 2011 , 11, 543-56		36
373	Development of the hepatitis C self-management program. 2011 , 83, 252-5		11
372	Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic Fatty liver disease. 2011 , 20, 149-56		9
371	Liver biopsies in chronic viral hepatitis: beyond grading and staging. 2011 , 135, 1320-8		16
370	Adipokines and redox signaling: impact on fatty liver disease. 2011 , 15, 461-83		47
369	Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. 2011 , 34 Suppl 2, S367-70		29
368	Peroxisome proliferator-activated receptors and hepatitis C virus. 2011 , 4, 419-31		9
367	Visceral abdominal and subfascial femoral adipose tissue have opposite associations with liver fat in overweight and obese premenopausal caucasian women. 2011 , 2011, 154672		11
366	Management of obesity and outcomes of hepatitis C treatment. 2011 , 1, 11-17		
365	Nonalcoholic Fatty Liver Disease. 2011 , 435-440		1
364	Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. 2011 , 286, 42615-42625		65
363	Impact of HCV genetic differences on pathobiology of disease. 2011 , 9, 747-59		31

- 362 The impact of host metabolic factors on treatment outcome in chronic hepatitis C. **2012**, 2012, 420156
- 361 Human subtilase SKI-1/S1P is a master regulator of the HCV Lifecycle and a potential host cell target for developing indirect-acting antiviral agents. **2012**, 8, e1002468 59
- 360 Study of liver pro-oxidant/antioxidant balance in aged female rats subjected to social isolation and reversibility of the changes by resocialization. **2012**, 11, 54-61
- 359 Hepatic steatosis in HCV infection genotype 4 in Egypt. **2012**, 2, 16-21 0
- 358 Tumours and tumour-like lesions of the liver. **2012**, 761-851 19
- 357 Increased α -Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4. **2012**, 2012, 636392 6
- 356 Correlation between level of viremia and insulin resistance in patients with chronic hepatitis C virus (genotype 4) infection. **2012**, 2, 37-40
- 355 Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. **2012**, 26, 1509-16 18
- 354 Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. **2012**, 7, e29370 30
- 353 The interaction of metabolic factors with HCV infection: does it matter?. **2012**, 56 Suppl 1, S56-65 137
- 352 Peginterferon- α 2B plus ribavirin is more effective than peginterferon- α 2A plus ribavirin in menopausal women with chronic hepatitis C. **2012**, 19, 640-9 7
- 351 Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. **2012**, 221, 496-502 141
- 350 Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. **2012**, 32, 1443-50 15
- 349 Impact of age on liver regeneration response to injury after partial hepatectomy in a rat model. **2012**, 175, e1-9 19
- 348 PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. **2012**, 13, 82 20
- 347 Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. **2012**, 10, 41 11
- 346 Hepatic steatosis in HIV-HCV coinfecting patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. **2012**, 5, 180 3
- 345 Combining semiquantitative measures of fibrosis and qualitative features of parenchymal remodelling to identify fibrosis regression in hepatitis C: a multiple biopsy study. **2012**, 61, 473-87 4

344	Autophagy protects cells from HCV-induced defects in lipid metabolism. 2012 , 142, 644-653.e3		57
343	The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. 2012 , 36, 13-20		157
342	Relation entre st�tose, activit�et fibrose au cours de l��patite chronique C. 2012 , 1		
341	Viral sequence variation in chronic carriers of hepatitis C virus has a low impact on liver steatosis. 2012 , 7, e33749		6
340	Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. 2012 , 3, 54		26
339	Body mass index and nonresponse to antiviral treatment in korean patients with genotype 2 and 3 chronic hepatitis C. 2012 , 48, 21-6		2
338	Nonalcoholic Fatty Liver Disease. 2012 , 941-968		3
337	Association of chronic viral hepatitis B with insulin resistance. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6120-6	5.6	27
336	MTP -493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients. 2012 , 45, 72-7		10
335	Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. 2012 , 142-156		1
334	Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. 2012 , 86, 6315-22		80
333	Recurrent hepatitis C after liver transplantation. 2012 , 79, 190-8		2
332	V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. <i>Hepatology</i> , 2012 , 55, 1473-84	11.2	38
331	Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. <i>Hepatology</i> , 2012 , 56, 49-56	11.2	59
330	Is there still a role for liver biopsy in managing hepatitis C virus infections?. 2012 , 1, 32-35		
329	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. 2012 , 35, 238-47		74
328	Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. 2012 , 42, 714-20		2
327	Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. 2012 , 35, 1434-42		32

326	Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. 2012 , 19, 244-53	142
325	Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. 2012 , 19, 278-82	23
324	Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon- α -2a plus ribavirin and RVR. 2012 , 19, 346-52	23
323	Alterations in NK cell phenotype in relation to liver steatosis in children with chronic hepatitis C. 2013 , 36, 1004-12	4
322	Strong correlation by ultrasonography of hepatomegaly and the presence of co-infection in HIV/HCV cirrhotic patients. 2013 , 17, 150-5	4
321	Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. 2013 , 27, 293-300	39
320	Blockade of B-cell-activating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity. 2013 , 93, 311-21	21
319	Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. 2013 , 20, 669-77	53
318	Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. 2013 , 13, 203	83
317	Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 311-7.e1 ^{6,9}	27
316	Lipids and HCV. 2013 , 35, 87-100	73
315	Leptin modulates lymphocytes' adherence to hepatic stellate cells is associated with oxidative status alterations. 2013 , 13, 473-80	6
314	Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C. 2013 , 12, 377-84	10
313	Optimal treatment with boceprevir for chronic HCV infection. 2013 , 33 Suppl 1, 14-22	8
312	Liver injury and disease pathogenesis in chronic hepatitis C. 2013 , 369, 263-88	49
311	The predictive value of steatosis in hepatitis C virus infection. 2013 , 7, 205-13	23
310	Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. 2013 , 5, 1292-324	99
309	Hepatotoxicity of Antiviral Agents. 2013 , 505-518	2

308	How the antiviral immune response boosts liver fat. 2013 , 19, 671-2		1
307	Hard clinical outcomes in patients with NAFLD. 2013 , 7 Suppl 2, 790-9		7
306	Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography. 2013 , 208, 1776-83		13
305	The hepatitis C self-management program: sustainability of primary outcomes at 1 year. 2013 , 40, 730-40		11
304	Metabolic factors and chronic hepatitis C: a complex interplay. 2013 , 2013, 564645		23
303	Prediction of sustained virologic responses to combination therapy of pegylated interferon- α and ribavirin in patients with chronic hepatitis C infection. 2013 , 20, 35-40		19
302	Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. 2013 , 85, 1913-8		11
301	Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. 2013 , 20, 517-23		44
300	Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. 2013 , 38, 415-23		91
299	Association of visceral obesity with high viral load and histological findings in elderly patients with genotype 1 chronic hepatitis C. 2013 , 52, 1665-73		5
298	Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C. 2013 , 25, 421-7		13
297	Non-B, non-C hepatocellular carcinoma (Review). 2013 , 43, 1333-42		45
296	Primary biliary cirrhosis is more severe in overweight patients. 2013 , 47, e28-32		23
295	Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. <i>World Journal of Hepatology</i> , 2013 , 5, 528-40	3-4	144
294	An insight into the diagnosis and pathogenesis of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7896-909	5.6	43
293	Impact of IL28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. 2013 , 8, e80172		22
292	Reasons for Nonattendance across the Hepatitis C Disease Course. 2013 , 2013, 579529		3
291	Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients. 2013 , 12, 871-875		8

290	Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) of 3.0T in assessment of steatosis to antiviral therapy for chronic hepatitis C. 2014 , 13, 4753-4760		
289	Influence of hepatitis C virus and IL28B genotypes on liver stiffness. 2014 , 9, e115882		6
288	Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15992-6013	5.6	27
287	Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. 2014 , 5, 586-600		66
286	Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C. 2014 , 2014, 517820		10
285	Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?. 2014 , 21, 1-8		23
284	Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. 2014 , 61, S69-78		107
283	Stàtose hãpatique lors du syndrome mãtabolique chez l'adulte noir africain : cas du Burundi. 2014 , 8, 195-199		3
282	Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients. 2014 , 26, 788-94		9
281	Central portalization correlates with fibrosis but not with risk factors for nonalcoholic steatohepatitis in steatotic chronic hepatitis C. 2014 , 2014, 329297		5
280	Atherosclerosis as a possible extrahepatic manifestation of chronic hepatitis C virus infection. 2014 , 8, 1-5		9
279	The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid droplets. 2014 , 289, 35770-80		25
278	Comparison between transient elastography (Fibroscan) and liver biopsy for the diagnosis of hepatic fibrosis in chronic hepatitis C genotype 4. 2014 , 4, 106-111		7
277	Transmission dynamics of hepatitis C virus among intra venous drug users in the border state of Manipur, India. 2014 , 24, 57-67		7
276	Quantification of portal-bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. 2014 , 27, 1035-45		16
275	Natural history of hepatitis C. 2014 , 61, S58-68		524
274	Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection. 2014 , 33, 1725-32		20
273	Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. 2014 , 59, 1586-93		47

272	The impact of obesity and metabolic syndrome on chronic hepatitis C. 2014 , 18, 147-56		20
271	Association between hepatitis B virus infection and metabolic syndrome: a retrospective cohort study in Shanghai, China. 2014 , 14, 516		9
270	A meta-analysis of the association between gestational diabetes mellitus and chronic hepatitis B infection during pregnancy. 2014 , 7, 139		11
269	Is genotype 3 of the hepatitis C virus the new villain?. <i>Hepatology</i> , 2014 , 59, 2403-12	11.2	96
268	Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 334-40	6.9	40
267	Review article: HCV genotype 3 – the new treatment challenge. 2014 , 39, 686-98		93
266	Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. 2014 , 44, E137-44		17
265	Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. 2014 , 14, 121-31		46
264	Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B. 2015 , 47, 2886-91		11
263	Insulin resistance and its consequences in chronic hepatitis C. 2015 , 1, 17-29		9
262	Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 12989-95	5.6	47
261	Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture. 2015 , 10, e0125962		19
260	Substitution in Amino Acid 70 of Hepatitis C Virus Core Protein Changes the Adipokine Profile via Toll-Like Receptor 2/4 Signaling. 2015 , 10, e0131346		11
259	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. 2015 , 10, e0137351		19
258	Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. 2015 , 2015, 758164		14
257	Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. 2015 , 14, 75-82		36
256	Viral Hepatitis. 2015 , 1439-1468.e7		4
255	ASSOCIATION OF THE NUTRITIONAL PROFILE WITH HISTOLOGICAL FINDINGS OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION. 2015 , 52, 315-20		

254	Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. 2015 , 14, 826-36		16
253	Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. 2015 , 60, 3005-10		10
252	Chronic hepatitis C, depression and gender: a state of art. 2015 , 8, 193-210		3
251	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. 2015 , 26, 30-6		30
250	Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?. 2015 , 9, 5-8		2
249	TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. 2015 , 35, 1959-63		43
248	Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. 2015 , 110, 1169-77; quiz 1178		30
247	Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy. 2015 , 211, 1429-36		7
246	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015 , 62, 111-7	11.2	46
245	Patatin-like phospholipase domain containing-3 gene (PNPLA3) I148M polymorphism and liver damage in chronic hepatitis C Egyptian patients. 2015 , 16, 333-341		1
244	Increased circulating adiponectin in males with chronic HCV hepatitis. 2015 , 26, 635-9		5
243	Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. 2015 , 149, 1454-1461.e1		160
242	Natural History of Hepatitis C. 2015 , 44, 717-34		121
241	Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?. 2015 , 149, 1326-30		1
240	PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. 2015 , 62, 763-70		28
239	Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis. 2015 , 62, 879-88		50
238	Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'. 2015 , 9, 375-85		14
237	The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. 2016 , 19, 91-8		3

236	NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. 2016 , 17,		50
235	Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. <i>World Journal of Hepatology</i> , 2016 , 8, 1557-1563	3.4	31
234	REDUCED HAND GRIP STRENGTH IN OVERWEIGHT AND OBESE CHRONIC HEPATITIS C PATIENTS. 2016 , 53, 31-5		2
233	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. 2016 , 17, 355		30
232	Hepatitis C Virus, Insulin Resistance, and Steatosis. 2016 , 4, 66-75		56
231	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9674-9693	5.6	69
230	Impact of obesity and diabetes on waitlist survival, probability of liver transplantation and post-transplant survival among chronic hepatitis C virus patients. 2016 , 36, 1167-75		11
229	Significance of Hepatic Insulin Clearance in Patients with Chronic Hepatitis C and Non-alcoholic Fatty Liver Disease. 2016 , 55, 1049-54		5
228	Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). <i>Hepatology</i> , 2016 , 63, 1430-41	11.2	201
227	Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. 2016 , 13, 328-339		13
226	Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. 2016 , 2, 21		6
225	Chronic viral hepatitis C in pediatric age group; assessment of viral activity and hepatic fibrosis by 1H magnetic resonance spectroscopy and diffusion weighted imaging in asymptomatic patient. 2016 , 47, 739-748		1
224	The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. 2016 , 221, 746-54		48
223	Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. 2016 , 44, 1242-1252		25
222	Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin. <i>Antiviral Therapy</i> , 2017 , 22, 237-246	1.6	15
221	Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study. 2016 , 65, 363-8		48
220	Awareness of Hepatitis C Virus Seropositivity and Chronic Infection in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). 2016 , 18, 1257-1265		8
219	Hepatitis C Virus Genotype and Subtype Distribution in Patient Specimens Tested at the University of Texas Medical Branch, Galveston, Between January 2011 and November 2014. 2016 , 47, 112-8		2

218	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. 2016 , 48, 333-42	42
217	Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. 2016 , 10, 13-20	5
216	Pathophysiology of lipid droplet proteins in liver diseases. 2016 , 340, 187-92	84
215	Viability of pegIFN- α -RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment. 2017 , 29, 94-101	0
214	Atherosclerosis in chronic hepatitis C virus patients with and without liver cirrhosis. 2017 , 69, 139-147	5
213	Impact of hepatitis C virus therapy on metabolism and public health. 2017 , 37 Suppl 1, 13-18	19
212	Genotype 3 Infection: The Last Stand of Hepatitis C Virus. 2017 , 77, 131-144	31
211	Sonography Predicts Liver Steatosis in Patients With Chronic Hepatitis B. 2017 , 36, 925-932	9
210	Lipid droplets and liver disease: from basic biology to clinical implications. 2017 , 14, 343-355	245
209	The Role of Senescence in Hepatic Diseases. 2017 , 295-308	
208	Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. 2017 , 65, 13-19	20
207	Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. 2017 , 62, 2159-2165	5
206	Comparison of correlations between lipid profile and different computed tomography fatty liver criteria in the setting of incidentally noted fatty liver on computed tomography examinations. 2017 , 29, 1389-1396	5
205	TRIF-dependent Toll-like receptor signaling suppresses transcription in hepatocytes and prevents diet-induced hepatic steatosis. 2017 , 10,	10
204	The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. 2017 , 7, 9273	14
203	Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. 2017 , 89, 1973-1980	8
202	Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. 2017 , 13, 2695-2706	16
201	Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression. 2017 , 96, e5832	7

200	Hepatitis C Genotype 3 Infection: Pathogenesis and Treatment Horizons. 2017 , 21, 645-657	4
199	Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. 2017 , 17, 235	9
198	Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. 2017 , 17, 361	10
197	Hepatitis C. 2017 , 628-698	
196	Association between visceral obesity and hepatitis C infection stratified by gender: a cross-sectional study in Taiwan. 2017 , 7, e017117	1
195	Is Senescence Important in Hepatic Diseases?. 2017 ,	
194	Endemic hepatitis B and C virus areas are associated with lower prevalence of hyperlipidemia: Ecological and cross-sectional studies. 2017 , 4, 54-60	
193	Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfecting patients. 2017 , 12, e0181890	7
192	Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. 2017 , 14, 45-52	11
191	PNPLA3 expression and its impact on the liver: current perspectives. 2017 , 9, 55-66	42
190	Paediatric fatty liver disease (PeFLD): All is not NAFLD - Pathophysiological insights and approach to management. 2018 , 68, 1286-1299	26
189	Structural and Epitope Analysis (T- and B-Cell Epitopes) of Hepatitis C Virus (HCV) Glycoproteins: An Approach. 2018 , 8, 352-361	4
188	High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. 2018 , 67, 1536-1542	43
187	Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial. <i>Hepatology</i> , 2018 , 67, 514-523	11.2 96
186	The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. 2018 , 38, 1064-1073	8
185	Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. 2018 , 33, 1379-1382	45
184	In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections. 2018 , 25, 262-271	2
183	Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. 2018 , 30, 291-295	6

182	Epidemiology, Natural History, and Diagnosis of Hepatitis C. 2018 , 428-445.e8	0
181	Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. 2018 , 13, e0206947	9
180	Serum leptin and homeostasis model assessment-IR as novel predictors of early liver fibrosis in chronic hepatitis B virus infection. 2018 , 75, 192-196	4
179	Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017). 2018 , 13, e0208839	11
178	Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. 2018 , 31, 541-551	8
177	Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. 2018 , 8, 7845	14
176	In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and/or expansion of HIV infection. 2018 , 19, 597-604	3
175	Endotoxemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. 2018 , 46, 793-799	10
174	Identification of potential anti-hepatitis C virus agents targeting non structural protein 5B using computational techniques. 2018 , 119, 8574-8587	2
173	Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. 2018 , 8, 7164	9
172	Gallic Acid as a Putative Antioxidant in Usage Against Liver Disease. 2018 , 317-322	1
171	Human Immunodeficiency Virus Infection of the Liver. 2018 , 247-264	
170	Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. 2019 , 51, 142-148	1
169	Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. 2019 , 9, 10596	11
168	Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. 2019 , 45, 2679-2687	54
167	HCV infection causes cirrhosis in human by step-wise regulation of host genes involved in cellular functioning and defense during fibrosis: Identification of bio-markers. 2019 , 6, 304-317	4
166	Hepatitis C virus 3b strains in injection drug users in Guangdong Province, China, may have originated in Yunnan Province. 2019 , 164, 1761-1770	3
165	Hepatitis C virus infection and risk of coronary artery disease: A meta-analysis. 2019 , 63, 69-73	7

164	Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance. 2019 , 93,	7
163	The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. 2019 ,	3
162	Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. 2019 , 212, 332-341	34
161	Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis. 2019 , 26, 337-349	24
160	Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis. 2020 , 10,	5
159	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis. 2020 , 50, 190-198	14
158	Hepatitis C, systemic inflammation and oxidative stress: correlations with metabolic diseases. 2020 , 14, 27-37	7
157	Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment. 2020 , 10, 114-123	
156	Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C. 2020 , 53, 542-549	6
155	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. 2020 , 30, 2293-2301	29
154	Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop. 2020 , 83, 1565-1576	18
153	Insulin resistance in nondiabetic Egyptian patients with chronic hepatitis C virus. 2020 , 85, 173-179	1
152	Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years. 2020 , 179, 719-726	3
151	Liver fat quantification: where do we stand?. 2020 , 45, 3386-3399	14
150	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). 2021 , 53, 1301-1307	2
149	Diversity of the hepatitis C virus NS5B gene during HIV co-infection. 2020 , 15, e0237162	4
148	Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. 2020 , 52, 866-876	7
147	Effectiveness and safety of sofosbuvir/velpatasvir + ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. 2020 , 27, e41-e47	1

146	Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging-determined proton density fat fraction. 2020 , 50, 1319-1327	5
145	Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?. 2020 , 222, S802-S813	5
144	The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. 2020 , 2020, 8814135	2
143	Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease. 2020 , 19, 227-229	10
142	Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection. 2020 , 10, e035867	3
141	Hepatitis C virus genotypes 1-3 infections regulate lipogenic signaling and suppress cholesterol biosynthesis in hepatocytes. 2020 , 119, 1382-1395	0
140	A novel microRNA boosts hyper-oxidation of fatty acids in liver by impeding CEP350-mediated sequestration of PPAR β and thus restricts chronic hepatitis C. 2020 , 17, 1352-1363	2
139	Insulin resistance in nondiabetic Egyptian patients with chronic hepatitis C virus. 2020 , 85, 173-179	
138	The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. 2020 , 5, 253-263	
137	The hepatic lipidome: From basic science to clinical translation. 2020 , 159, 180-197	15
136	Blood-based gene expression profile of oxidative stress and antioxidant genes for identifying surrogate markers of liver tissue injury in chronic hepatitis C patients. 2020 , 165, 809-822	8
135	Clinicopathological features of hepatocellular carcinoma with fatty change: Tumors with macrovesicular steatosis have better prognosis and aberrant expression patterns of perilipin and adipophilin. 2020 , 70, 199-209	3
134	Hepatic Lipid Droplets in Liver Function and Disease. 2020 , 245-254	
133	Viral Escape Mechanisms in Hepatitis C and the Clinical Consequences of Persistent Infection. 2020 , 868-888	
132	The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. 2020 , 51, 1160-1168	9
131	Chronic Hepatitis. 2021 , 155-186	
130	Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study. 2021 , 11, 227-231	1
129	Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment. 2021 , 9, 35	2

128	Current Management of HCV Genotype 3 Infection. 2021 , 97-117		
127	Natural History of Hepatitis C Infection. 2021 , 151-174		
126	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). 2021 , 19, 1147-1156		1
125	Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1-3 Strains and Does Not Correlate with Virus Replication. 2021 , 13,		1
124	Genotype 3-hepatitis C virus' last line of defense. <i>World Journal of Gastroenterology</i> , 2021 , 27, 1006-1021.	5.6	3
123	Metabolic complications of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2021 , 27, 1267-1282	7	
122	Infections at the nexus of metabolic-associated fatty liver disease. 2021 , 95, 2235-2253		1
121	Relationship between symptoms and both stage of change in adopting a healthy life style and quality of life in patients with liver cirrhosis: a cross-sectional study. 2021 , 19, 148		0
120	Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. <i>Diagnostics</i> , 2021 , 11,	3.8	3
119	CC- chemokine ligand 25 mediates inflammatory crosstalk between adipose and liver in non-alcoholic fatty liver disease.		
118	Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection:. 2021 , 11, 700228		0
117	Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome. 2021 , 11, 14506		2
116	Disorders of lipid metabolism in the liver in patients with chronic viral hepatitis. 2021 , 13, 27-38		
115	Quantification of Liver Fat Content with CT and MRI: State of the Art. 2021 , 301, 250-262		10
114	Introduction. 2021 , 1-15		
113	Stellate Cells. 2011 , 53-79		4
112	Natural History of Chronic Hepatitis C. 2016 , 3-55		1
111	Chronic Viral Hepatitis. 2010 , 1593-1617		1

110	Hepatitis C infection: a clinical review. 2004 , 97, 364-73; quiz 374		25
109	Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH). 2018 , 25, 171-179		14
108	Role of genetic polymorphisms in hepatitis C virus chronic infection. <i>World Journal of Clinical Cases</i> , 2015 , 3, 807-22	1.6	12
107	Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C. 2014 , 9, e99450		13
106	HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. 2014 , 9, e103748		3
105	Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C. 2014 , 9, e106022		9
104	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. 2015 , 10, e0143429		19
103	Roles of Perilipins in Diseases and Cancers. 2018 , 19, 247-257		14
102	Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy. 2019 , 19, 1388-1398		2
101	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. 2019 , 110, 401-409		9
100	KASL clinical practice guidelines: management of hepatitis C. 2014 , 20, 89-136		30
99	KASL clinical practice guidelines: management of hepatitis C. 2016 , 22, 76-139		58
98	Hepatic steatosis: a benign disease or a silent killer. <i>World Journal of Gastroenterology</i> , 2008 , 14, 4120-6	5.6	49
97	Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. <i>World Journal of Gastroenterology</i> , 2009 , 15, 462-6	5.6	20
96	Viral and host causes of fatty liver in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2005 , 11, 3056-9	5.6	72
95	Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2005 , 11, 3357-62	5.6	14
94	Leptin administration exacerbates thioacetamide-induced liver fibrosis in mice. <i>World Journal of Gastroenterology</i> , 2005 , 11, 4822-6	5.6	17
93	Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. <i>World Journal of Gastroenterology</i> , 2005 , 11, 5944-50	5.6	11

92	Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus. <i>World Journal of Gastroenterology</i> , 2005 , 11, 6085-9	5.6	7
91	Changes in lipid metabolism in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2005 , 11, 6422-8	5.6	24
90	High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2006 , 12, 556-60	5.6	16
89	Mechanisms and significance of liver steatosis in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2006 , 12, 6756-65	5.6	115
88	Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2007 , 13, 5180-7	5.6	66
87	Steatosis as a co-factor in chronic liver diseases. <i>World Journal of Gastroenterology</i> , 2010 , 16, 1171-6	5.6	32
86	Serum leptin and ghrelin in chronic hepatitis C patients with steatosis. <i>World Journal of Gastroenterology</i> , 2011 , 17, 5097-104	5.6	8
85	Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. <i>World Journal of Gastroenterology</i> , 2012 , 18, 212-24	5.6	41
84	Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6947-56	5.6	11
83	PNPLA3 I148M polymorphism and progressive liver disease. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6969-78	5.6	153
82	Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2825-38	5.6	30
81	Interaction between hepatitis C virus and metabolic factors. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2888-901	5.6	48
80	Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5773-93	5.6	27
79	Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7089-103	5.6	66
78	Hepatitis C virus infection in the human immunodeficiency virus infected patient. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12132-43	5.6	20
77	Mechanisms of intrahepatic triglyceride accumulation. <i>World Journal of Gastroenterology</i> , 2016 , 22, 1664-73	5.6	57
76	Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. <i>World Journal of Gastroenterology</i> , 2018 , 24, 1269-1277	5.6	27
75	Relationship between the production of autoantibodies to oxidized low-density lipoprotein and hepatic steatosis in patients with chronic hepatitis C. 2010 , 1, 663-668		6

74	Nonalcoholic fatty liver disease. 2006 , 35, 290-4, 297-9		12
73	The effect of NAFLD (non-alcoholic fatty liver disease) on long-term outcome of chronic hepatitis B in Iranian patients. 2012 , 02, 18-21		5
72	Polymorphisms in methylenetetrahydrofolate reductase gene: Their impact on liver steatosis and fibrosis of chronic hepatitis c patients. 2014 , 04, 73-80		1
71	Hepatitis C virus infection and insulin resistance. 2014 , 5, 52-8		69
70	Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. <i>World Journal of Hepatology</i> , 2013 , 5, 74-81	3-4	18
69	Strategies to reduce hepatitis C virus recurrence after liver transplantation. <i>World Journal of Hepatology</i> , 2013 , 5, 237-50	3-4	12
68	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. <i>World Journal of Hepatology</i> , 2014 , 6, 677-84	3-4	14
67	Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. <i>World Journal of Hepatology</i> , 2015 , 7, 44-52	3-4	13
66	Liver steatosis in hepatitis C patients. <i>World Journal of Hepatology</i> , 2015 , 7, 1337-46	3-4	12
65	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. <i>World Journal of Hepatology</i> , 2015 , 7, 2543-50	3-4	8
64	Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis. <i>World Journal of Hepatology</i> , 2016 , 8, 74-82	3-4	5
63	Hepatitis C virus (HCV) infection and hepatic steatosis. 2006 , 3, 53-6		43
62	The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. 2021 , 9,		2
61	Role of Core Protein-Induced Oxidative Stress in the Pathogenesis of Hepatitis C. 2003 , 8-18		
60	NASH. 2006 , 1031-1063		1
59	Efficacy of Pegylated Interferon and Ribavirin Combination Therapy in Chronic Hepatitis C and Influence of Lipid Factors. 2008 , 34, 355-360		
58	Fat and viral liver disease. 2009 , 41-49		
57	Hepatitis C in Special Populations. 2009 , 97-134		

- 56 Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. **2009**, 104, 605-616 4
- 55 Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. **2009**, 104, 598-604 3
- 54 Epidemiology of the Hepatocellular Carcinoma. **2009**, 1-8
- 53 Diabetes and Liver Disease. **2010**, 557-577
- 52 Chronic Hepatitis. **2010**, 133-161
- 51 Hepatitis C Virus.
- 50 Gastrointestinal Diseases Associated with Substance Addiction. 313-338
- 49 Human Immunodeficiency Virus Infection. **2011**, 273-288 1
- 48 Evaluation of Serum Lipid Profile in Turkish Patients with Chronic Hepatitis C. **2011**, 8, 7-12
- 47 Hepatitis C. 582-652
- 46 Chronic HCV and Steatosis. **2012**, 35-45
- 45 Hepatitis C Virus Genotypes. 12-16 1
- 44 [Chronic hepatitis C and insulin resistance]. *Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The*, **2012**, 59, 268-74 0.6
- 43 Hepatitis Viruses: Hepatitis C. **2014**, 765-783
- 42 Biological Impact of Type I Interferon Induction Pathways beyond Their Antivirus Activity. 155-175
- 41 Hepatitis C virus capsid protein and intracellular lipids interplay and its association with hepatic steatosis. *Hepatitis Monthly*, **2014**, 14, e17812 1.8 5
- 40 Diabetes and Liver Disease. **2015**, 1-25
- 39 Chronic Hepatitis. **2016**, 145-174

38	The Multifaceted Features of HCV Infection Beyond the Liver. 2016 , 57-78		
37	Diabetes and Liver Disease. 2017 , 705-729		
36	Diabetes and Liver Disease. 2017 , 1-26		
35	The Role of Biochemical Variations and Genotype Testing in Determining the Virological Response of Patients Infected with Hepatitis C Virus. <i>Journal of Global Infectious Diseases</i> , 2018 , 10, 89-98	2.8	
34	The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. <i>Contemporary Endocrinology</i> , 2020 , 207-219	0.3	
33	ERKRANKUNGEN DER VERDAUUNGSORGANE. 2020 , pA-1-pA7.8-14		
32	Steatosis and hepatitis C. 173-179		
31	Treatment of Chronic Hepatitis C with Different Genotypes. 2008 , 130-147		2
30	The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology. 2008 , 229-244		
29	Hepatitis C virus infection and nonalcoholic steatohepatitis. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 305-12	0.7	20
28	Recurrence of Disease Following Liver Transplantation: Nonalcoholic Steatohepatitis vs Hepatitis C Virus Infection. <i>International Journal of Organ Transplantation Medicine</i> , 2011 , 2, 57-65	0.7	8
27	Prevalence of hepatic steatosis and associated factors in Iranian patients with chronic hepatitis C. <i>Medical Journal of the Islamic Republic of Iran</i> , 2016 , 30, 322	1.1	2
26	Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 293-9	0.7	12
25	Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. <i>Revista Espanola De Quimioterapia</i> , 2019 , 32, 137-144	1.6	3
24	Effects of alcohol consumption on viral hepatitis B and C.. <i>World Journal of Clinical Cases</i> , 2021 , 9, 10052-10063		
23	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDF in a Large Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
22	Hepatitis C virus: A critical approach to who really needs treatment.. <i>World Journal of Hepatology</i> , 2022 , 14, 1-44	3-4	
21	Diagnostic and prognostic significance of hepatic steatosis in patients with chronic hepatitis C.. <i>Romanian Journal of Morphology and Embryology</i> , 2021 , 62, 765-775	0.6	2

20	Sobrevida en pacientes con cirrosis de acuerdo con su etiología. Cohorte retrospectiva. <i>Revista Colombiana De Gastroenterología</i> , 2022 , 37, 24-32	0.2	0
19	Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response.. <i>Diagnostics</i> , 2022 , 12,	3.8	1
18	Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 894460	5.6	
17	Interferon-alfa: um interferente endógeno. 2021 , 95-122		
16	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 405-415	1.6	20
15	Influence of Hepatitis C Genotypes on Lipid Levels in HIV-Positive Patients during Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 521-527	1.6	7
14	Chronic Hepatitis C and Genotyping: The Clinical Significance of Determining HCV Genotypes. <i>Antiviral Therapy</i> , 2005 , 10, 1-11	1.6	102
13	Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease.. <i>Magnetic Resonance in Medical Sciences</i> , 2022 ,	2.9	
12	Metabolic aspects of hepatitis C virus. <i>World Journal of Gastroenterology</i> , 2022 , 28, 2429-2436	5.6	0
11	Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. <i>World Journal of Hepatology</i> , 2022 , 14, 1248-1257	3.4	
10	Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients. 2022 , 12,		
9	Diagnosis of hepatic steatosis based on ultrasound attenuation imaging is not influenced by liver fibrosis.		
8	Nicht-alkoholische Fettlebererkrankung als Komorbidität chronischer Lebererkrankungen. 2022 , 301-309		0
7	Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study. 13,		0
6	Impact of hepatic steatosis on treatment response of autoimmune hepatitis: A retrospective multicentre analysis. 13,		0
5	Role of bioactive compounds in the treatment of hepatitis: A review. 13,		0
4	The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis. 1-10		1
3	Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact. 2023 , 11, 271		1

2 Nutrition in liver disease. **2023**, 87-134

o

1 The Influence of Metabolic Factors in Patients with Chronic Viral Hepatitis C Who Received Oral Antiviral Treatment. **2023**, 13, 571

o